Form 4: Galera Therapeutics Director Reports Stock Transaction
Insider Transaction (Form 4)
Michael R. Friedman, a Director of Galera Therapeutics, Inc., reported multiple transactions in common stock on May 15, 2026.
Summary
- Conversion of derivative: acquired 2,989,399 Common Stock on May 15, 2026; holds 8,326,269 after (Indirect).
- Disposition to the issuer: disposed of 41,631 Common Stock on August 3, 2026 (Indirect).
- Conversion of derivative: disposed of 2,989 Series B Preferred Stock on May 15, 2026 (Indirect).
- Disposition to the issuer: disposed of 480 Stock Option (Right to Buy) on August 3, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Michael R. Friedman — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-05-15 | Conversion of derivative | Common Stock | 2,989,399 | — | — | 8,326,269 |
| 2026-08-03 | Disposition to the issuer | Common Stock | 41,631 | — | — | 0 |
| 2026-05-15 | Conversion of derivative | Series B Preferred Stock | 2,989.399 | — | — | 0 |
| 2026-08-03 | Disposition to the issuer | Stock Option (Right to Buy) | 480 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-05-15 | Conversion of derivative (2,989,399 shares) |
| 2026-08-03 | Disposition to the issuer (41,631 shares) |
| 2026-05-15 | Conversion of derivative (2,989 shares) |
| 2026-08-03 | Disposition to the issuer (480 shares) |
Keywords
insider transaction, Form 4, GRTX, Galera Therapeutics, Inc., neutral, Michael R. Friedman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.